Pardes Biosciences

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. It develops oral antiviral drugs to treat and prevent various infections caused by coronavirus. The firm's product candidate, PBI-0451, is being developed as a potential direct-acting and oral antiviral drug to treat and prevent SARS-CoV-2 infections and associated diseases. The company was founded by Uri A. Lopatin and Lee D. Arnold on February 27, 2020 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. It also focuses on developing novel drugs to solve pandemic-sized problems like the coronavirus disease. The company was founded by Uri A. Lopatin and Lee D. Arnold on February 27, 2020 and is headquartered in Carlsbad, CA.

CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes' outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.

Pardes Biosciences Announces Closing of Tender Offer

LARKSPUR, Calif.--(BUSINESS WIRE)-- #lifesciences--As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. (Nasdaq: PRDS) (“Pardes”) whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share in cash, plus a non-tradeable contingent value right (the “CVR”) associ.

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

LARKSPUR, Calif.--(BUSINESS WIRE)-- #lifesciences--As previously announced, on July 16, 2023, MediPacific Sub, Inc. (“Purchaser”) and MediPacific, Inc. (“Parent”), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the “Merger Agreement”) with Pardes Biosciences, Inc. (Nasdaq: PRDS) (“Pardes”) whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not mor.

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pardes Biosciences, Inc. (NasdaqGM: PRDS) to MediPacific, Inc. Under the terms of the proposed transaction, MediPacific will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amou.

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ: PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Pardes Biosciences, Inc. ("Pardes" or "the Company") (NASDAQ:PRDS) for potential breaches of fiduciary duty on the part of its directors and management in connection with the Company's agreement to be acquired by MediPacific, Inc. ("MediPacific"). The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Pardes Biosciences, Inc. (NASDAQ: PRDS) to MediPacific, Inc. is fair to Pardes shareholders. Per the terms of the agreement, MediPacific would acquire all outstanding shares of Pardes for not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share at closing, plus a non-tradeable contingent value right representing the right to receive 80% of the net proc.

PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders

MILWAUKEE , July 17, 2023 /PRNewswire/ -- Ademi LLP is investigating Pardes (Nasdaq: PRDS) for possible breaches of fiduciary duty and other violations of law in its transaction with MediPacific.  Click here to learn how to join the action https://www.ademilaw.com/case/pardes-biosciences-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Pardes Biosciences, Inc. has obtained a Fair Price in its transaction with MediPacific

Pardes Biosciences Inc.'s PRDS, -0.54% stock was up 12.4% in premarket trades Monday after the clinical-stage biopharmaceutical company said it agreed to be acquired by MediPacific Inc. for up to $2.19 a share. The purchase price is not less than $2.02 a share in cash and an additional cash amount of not more than 17 cents per share, with the final price per share being based on the amount of the company's net cash at closing, plus a non-tradeable contingent-value right associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.

Pardes Biosciences stock rallies on buyout offer from MediPacific

CARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. (Purchaser) will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company's net cash at closing, plus a non-tradeable contingent value right (the CVR) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

Pardes Biosciences, Inc. (PRDS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to Buy

Pardes Biosciences Seeking Strategic Alternatives. Pardes' Pipeline is depleted.

Pardes Biosciences Seeking Strategic Alternatives

CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023.

Pardes Biosciences Reports First Quarter 2023 Financial Results

Pardes Biosciences is a busted biopharma that is exploring strategic alternatives and trades at a wide 30% discount to its net cash. The company recently received a buyout proposal from its major shareholder/SPAC sponsor.

Pardes Biosciences: Strategic Review Is Likely To End Up In A Privatization

Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

Data from ongoing Phase 2 trial evaluating pomotrelvir (formerly known as PBI-0451) for  the treatment of COVID-19 expected in the coming weeks

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of COVID-19, announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 10:40 a.m. PT / 1:40 p.m. ET.

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

Aemetis

Blue Apron

Biora Therapeutics Inc

Faraday Future Intelligent Electric

Gossamer Bio Inc

SmileDirectClub

Sientra

Tattooed Chef

Vroom

More short squeeze penny stocks to watch before February 2023. The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch With High Short Interest This Week

BERWYN, Pa. , Jan. 30, 2023 /PRNewswire/ --  RM LAW, P.C.

RM LAW Announces Investigation of Pardes Biosciences, Inc.

Assembly Biosciences

BOSTON--( BUSINESS WIRE )--Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D.

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected in first quarter of 2023 Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected in first quarter of 2023

News for Pardes Biosciences Stock (PRDS)